Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.
about
Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodiesDrug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia?Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trialTargeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.The neurobiology of dopamine receptors: evolution from the dual concept to heterodimer complexesPSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor traffickingCell type-specific plasticity of striatal projection neurons in parkinsonism and L-DOPA-induced dyskinesia.Brain morphometry and the neurobiology of levodopa-induced dyskinesias: current knowledge and future potential for translational pre-clinical neuroimaging studies.Neuroimaging in Parkinson disease: from research setting to clinical practice.Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia.Striatal proteomic analysis suggests that first L-dopa dose equates to chronic exposure.Chronic NMDA administration to rats increases brain pro-apoptotic factors while decreasing anti-Apoptotic factors and causes cell death.Potential future neuroprotective therapies for neurodegenerative disorders and stroke.Maladaptive striatal plasticity in L-DOPA-induced dyskinesia.Dopamine receptor activation reveals a novel, kynurenate-sensitive component of striatal N-methyl-D-aspartate neurotoxicity.Roles of Ca(2+)/calmodulin-dependent protein kinase II in subcellular expression of striatal N-methyl-D-aspartate receptors in l-3, 4-dihydroxyphenylalanine-induced dyskinetic rats.Dieldrin exposure induces oxidative damage in the mouse nigrostriatal dopamine system.MPX-004 and MPX-007: New Pharmacological Tools to Study the Physiology of NMDA Receptors Containing the GluN2A Subunit.Discovery of 3-substituted aminocyclopentanes as potent and orally bioavailable NR2B subtype-selective NMDA antagonists.Targeting the D1-N-methyl-D-aspartate receptor complex reduces L-dopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson's ratsChronic NMDA administration increases neuroinflammatory markers in rat frontal cortex: cross-talk between excitotoxicity and neuroinflammation.Differences in excitatory transmission between thalamic and cortical afferents to single spiny efferent neurons of rat dorsal striatumNew pharmacological avenues for the treatment of L-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors.Scaffolding proteins of the post-synaptic density contribute to synaptic plasticity by regulating receptor localization and distribution: relevance for neuropsychiatric diseases.Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease.Motor cortical plasticity in Parkinson's disease.Levodopa-induced dyskinesias in Parkinson's disease: emerging treatmentsDyskinesias in Parkinson's disease: views from positron emission tomography studies.Therapeutic potential of targeting glutamate receptors in Parkinson's disease.Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.Current Nondopaminergic Therapeutic Options for Motor Symptoms of Parkinson's Disease.Design, synthesis, and structure-activity relationship of a novel series of GluN2C-selective potentiators.Investigational drugs in Phase I and Phase II for Levodopa-induced dyskinesias.Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism.GluN2A and GluN2B NMDA receptor subunits differentially modulate striatal output pathways and contribute to levodopa-induced abnormal involuntary movements in dyskinetic ratsNMDA receptor GluN2A/GluN2B subunit ratio as synaptic trait of levodopa-induced dyskinesias: from experimental models to patients.Mathematical insights into the effects of levodopa.Exogenous Alpha-Synuclein Alters Pre- and Post-Synaptic Activity by Fragmenting Lipid Rafts.Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.Striatal histone modifications in models of levodopa-induced dyskinesia.
P2860
Q24642126-764786D6-E6A5-4A53-BA9B-709DDA414E91Q27021464-A6927DD7-446F-43FE-8D1F-9FCB14409609Q27312728-F56A6EE4-8838-436F-BDE4-1B692999F89EQ27324174-FDE541A5-7845-47E6-8C82-CA8E8007D462Q28289714-8BEE964C-4262-4008-8898-D76C533200D9Q28582674-0D47D10B-9D8B-45D7-B181-6724EE3A8D62Q30650489-17663934-C367-4498-9E60-5682C9547A99Q30833645-6EA6933C-84E5-4F52-A94C-39D47CCCD804Q30868628-7EAA8068-66DC-4460-AE8B-CB9E96D85656Q33255884-88CBDC77-877E-4662-B818-DF61AB67FD32Q33319566-438EA847-DCBA-4C30-826A-D17B279CB3B9Q33507174-D5589B38-B580-4057-AE40-5B286C7BA0A6Q33687436-3A1269C9-6C4E-41B3-AB19-F9232257CC00Q34094008-41754BEC-4492-4751-85D3-2A82107C3550Q34654483-0CA12A1C-5AE1-40D8-870F-1E016D5F6978Q35492255-BAAD7C41-E8B0-49B0-83D4-A26FD9678EC2Q35850734-146CB032-59CF-4A4A-8CC6-8DE07002D4E6Q35909724-FE472143-2241-4B76-BC22-BBB3CB113058Q36015381-D7AFCF98-2BDB-4274-9D66-375E2E9A5E9BQ36557687-2819F3B7-3371-45B9-AAE7-15171E3B23FAQ36953315-AC852D9F-22D9-4EE7-8D43-88658DC3D302Q37000735-0612EF60-E1EF-480F-884C-34709932D1B1Q37974709-015BF6B6-3039-4C8E-BF9C-4F39C5606BFCQ38044699-564AB62F-0A96-428D-A54D-10E7E8967E37Q38056852-18308D9C-47C1-48DD-B29A-8BC27D844254Q38136650-F31B63C1-D095-40C3-AE9D-1CD3603A876EQ38156760-D56155C2-2CC0-4122-A3FD-6AD00B3E3B42Q38182651-8490EFED-BBFE-4BAA-9019-3F58CCC5912BQ38190016-5184F80D-FD82-4A8F-B6C0-36D05A31E856Q38262418-74425E0F-F53F-44C1-9D40-CEF50850B4B5Q38658203-FBC19950-D8FF-4DDA-B3E6-2701E066C580Q38705814-55F1401F-82E8-4FC6-ADE5-7D5B3A23365BQ39324877-7FDB6E6C-D4D6-438D-B857-E456F428F5CAQ40053132-39912B57-0175-41BA-AEB5-0F4EFEC94243Q40789803-862D731E-1311-49CD-9803-458D7DFD6BBCQ41420806-7469E6DD-8BEE-4E1E-B3CC-8D789C2DA2D4Q42224924-768FFE6E-5EBA-4247-BAA8-7C00A5DB2163Q42705823-901CA15F-CA9E-4FE0-93E4-C99C9BC478A7Q44050418-EE71CC72-755B-4FBF-AB6F-8F6E5457D169Q44228322-42498A5D-6051-4877-A07E-E804CBCAAFA2
P2860
Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Alterations of striatal NMDA r ...... model of Parkinson's disease.
@en
Alterations of striatal NMDA r ...... model of Parkinson's disease.
@nl
type
label
Alterations of striatal NMDA r ...... model of Parkinson's disease.
@en
Alterations of striatal NMDA r ...... model of Parkinson's disease.
@nl
prefLabel
Alterations of striatal NMDA r ...... model of Parkinson's disease.
@en
Alterations of striatal NMDA r ...... model of Parkinson's disease.
@nl
P2093
P50
P921
P1433
P1476
Alterations of striatal NMDA r ...... model of Parkinson's disease.
@en
P2093
Brotchie JM
Crossman AR
Ravenscroft P
P304
P356
10.1016/J.NEUROPHARM.2004.11.008
P577
2005-03-01T00:00:00Z